TOBI-based molecule

About HCW Biologics

HCW Biologics is developing a novel class of fusion immunotherapies targeting the interconnected biology of chronic inflammation and aging. Founded by Dr. Hing C. Wong, whose prior discovery led to the FDA-approved immunotherapy Anktiva, the company leverages two proprietary protein engineering platforms to create multi-functional biologics. Its strategy encompasses advancing internal clinical candidates while also commercializing platform-derived reagents for next-generation cell therapy manufacturing, aiming to create value through both therapeutic development and strategic partnerships.

Therapeutic Areas